Yesterday it was legal to put it in food. Today the government says it has to come out. So what exactly changed—the chemical, or our understanding of it?
That's one of the most important questions consumers can ask about food regulation.
Because history contains multiple examples of substances that were legally used before regulators reconsidered them.
That doesn't automatically mean government officials knew they were dangerous and deliberately allowed people to consume them.
It means regulatory science changes.
And if regulatory conclusions can change, consumers should understand how—and how quickly—that process happens.
01CONSIDER BROMINATED VEGETABLE OIL
Brominated vegetable oil, or BVO, was historically used in certain beverages to help keep citrus flavoring evenly distributed.
Its regulatory history lasted decades.
Additional research eventually caused FDA to reconsider whether continued authorization remained justified.
FDA revoked authorization for BVO in food in 2024 after concluding that there was no longer a basis to consider its intended use safe.
That's a significant sentence.
It doesn't mean:
“Every person who consumed BVO was injured.”
It means the evidence no longer supported the safety determination necessary for continued authorized use.
That's how scientific regulation is supposed to work.
But it also exposes a reality consumers often overlook:
Permission can be temporary because scientific knowledge is temporary.
02THE CHEMICAL DIDN’T CHANGE
BVO didn't transform chemically the day the regulation changed.
What changed was the evidence and its interpretation.
This is why saying:
“Don't worry, it's legal”
isn't a complete scientific argument.
It may be reassuring.
It may indicate that regulators currently consider the permitted use acceptable.
But it cannot mean that no future evidence could alter that conclusion.
History proves otherwise.
03RED NO. 3 IS EVEN MORE INSTRUCTIVE
Red No. 3 has been used to give foods a bright red appearance.
In January 2025, FDA revoked its authorization in food and ingested drugs.
Immediately, headlines appeared suggesting that government had finally admitted an ingredient was causing cancer.
The actual story is more nuanced.
High-dose studies had produced cancer in male laboratory rats.
But FDA also explained that the biological mechanism involved appears specific to male rats and that available evidence did not establish the same cancer effect in humans at ordinary exposure.
So why revoke it?
Because of the legal standard contained in the Delaney Clause.
That law prohibits authorization of certain additives shown to induce cancer in humans or animals.
The important lesson is that:
Hazard, actual human risk and regulatory legality can be three different questions.
04WHY DOES THAT MATTER?
Because both sides can misuse a story like Red No. 3.
A critic can say:
“FDA admitted this food dye gives people cancer.”
That's stronger than the evidence establishes.
A defender can say:
“There is absolutely nothing to worry about because FDA allowed it for decades.”
That ignores the fact that authorization was ultimately revoked.
The responsible conclusion is:
There was evidence sufficient to trigger a statutory prohibition, while FDA simultaneously maintained that the available evidence did not establish the same cancer mechanism in humans at typical exposure.
That's less dramatic.
It's also much harder to discredit.
Evidence still has to decide that.
05THIS IS WHY SCIENCE NEEDS REASSESSMENT
The food supply isn't static.
Neither is toxicology.
If regulators authorize a substance in 1980, that conclusion shouldn't become sacred simply because forty years have passed.
The question should be:
What does the best available evidence say now?
FDA's 2026 post-market assessment initiative is important precisely because it creates a more systematic mechanism for revisiting chemicals already in the food supply.
BHT and ADA became early subjects of that new reassessment program.
That should be welcomed.
But it should also lead to another question:
How many important reassessments should have happened sooner?
06SPEED MATTERS—BUT SO DOES GETTING IT RIGHT
It's tempting to say regulators should immediately ban any substance associated with a concerning study.
That would be reckless.
Scientific studies can be wrong.
Animal results may not translate to humans.
Cell experiments can use concentrations impossible to achieve through ordinary food consumption.
Observational studies can confuse correlation with causation.
Results can fail replication.
Regulators therefore need time to examine evidence carefully.
But excessive delay carries risks too.
If credible evidence of harm accumulates while millions remain exposed, bureaucratic slowness can have real consequences.
The challenge is balancing two errors:
Act too quickly and you can prohibit useful substances based on weak evidence.
Act too slowly and you can expose people unnecessarily while waiting for certainty that science may never provide.
There is no perfect formula.
But transparency can help.
07SHOW US THE CLOCK
When credible concerns emerge, consumers should be able to see:
When was the concern first identified?
When did FDA begin reviewing it?
What evidence is missing?
Who is responsible for generating that evidence?
When is the reassessment expected to finish?
What would trigger immediate action?
Why is the substance still permitted during review?
Those are reasonable questions.
Government agencies frequently ask citizens to trust their expertise.
Citizens should be able to ask agencies to show their work.
08INDUSTRY CAN MOVE FASTER THAN GOVERNMENT
Another complication is that companies sometimes remove controversial ingredients voluntarily before regulators require them to.
That can happen for several reasons.
Consumer pressure.
Litigation risk.
International harmonization.
Brand reputation.
Changing scientific evidence.
Or simply because an alternative ingredient makes continued controversy unnecessary.
This demonstrates that consumers possess a form of regulatory power too.
Purchasing decisions can change formulations before laws do.
But consumers can only exercise that power when they know what's in the product and understand the debate surrounding it.
09FOLLOWING THE MONEY BEGINS HERE
Manufacturers obviously have financial interests.
If an ingredient reduces production costs, extends shelf life, improves appearance or makes manufacturing easier, removing it may have economic consequences.
That doesn't mean companies knowingly sell harmful food.
It means companies operate under incentives.
Government does too.
Regulators operate with limited budgets.
Researchers pursue grants.
Politicians respond to voters, donors and lobbying.
Advocacy groups raise money around issues.
Everyone exists inside an incentive structure.
That's why “follow the money” is useful—but only if you follow it in every direction.
10DON'T CONFUSE INCENTIVES WITH PROOF OF CORRUPTION
This distinction will become critical later in this series.
If a food company financially benefits from an additive, that is a potential conflict or incentive worth understanding.
It does not prove its scientific claims are false.
Likewise, if an activist organization raises money campaigning against an ingredient, that doesn't prove its concerns are false.
Financial incentives tell us where to look more carefully.
They don't tell us what conclusion to reach.
Evidence still has to decide that.
11NOW ASK A BIGGER QUESTION
So far, we've been talking about food.
Substances people may consume routinely, often without thinking about them.
Now change the scenario.
Suppose an informed adult intentionally wants to take a biologically active compound because they believe it could help an injury, recovery, metabolism or another medical problem.
Suddenly the regulatory standard becomes much higher.
There are good reasons for that.
A drug is designed to alter physiology.
Injected products raise sterility issues.
Dose accuracy matters.
Impurities matter.
Immune reactions matter.
Interactions matter.
Manufacturing consistency matters.
Clinical efficacy matters.
Long-term safety matters.
Drugs should face rigorous standards.
But that leads to a question worth exploring:
How much uncertainty should an informed adult be allowed to voluntarily accept?
That brings us directly to peptides.
Next: Peptides Aren’t New—So Why Does the Debate Sound Like They Are?
Research sourcing: a separate question
SAVREN Labs supplies research materials. When evaluating any peptide supplier, ask for independently verifiable identity, purity, and batch-testing documentation. Supplier claims alone do not establish trustworthiness, clinical effectiveness, or safety for human use. Research materials are not substitutes for approved medicines or professional medical care.
Sources & Further Reading
Editorial note
The photographs are AI-generated editorial illustrations, not documented products or evidence of their ingredients. This article is educational analysis, not individual medical advice.